Nutritional Intervention Study with Argan Oil in Man: Effects on Lipids and ApolipoproteinsDerouiche A. · Cherki M. · Drissi A. · Bamou Y. · El Messal M. · Idrissi-Oudghiri A. · Lecerf J.M. · Adlouni A.
aLaboratoire de Recherche sur les Lipoprotéines, Faculté des Sciences Ben M’Sik, Casablanca, bHôpital Militaire Moulay Ismail, Meknès, et cLaboratoire de Biochimie, Faculté des Sciences Aïn Chock, Casablanca, Maroc; dService de Nutrition, Institut Pasteur de Lille, Lille, France
Aim: To evaluate whether the consumption of virgin argan oil (VAO) is associated with a change in serum lipids and reduces the risk of cardiovascular disease in healthy Moroccans. Methods: Sixty volunteers consumed butter (25 g/day) during 2 weeks (stabilization period) and were randomly divided into two groups: the treatment group received 25 g/day of VAO during 3 weeks (intervention period), and the control group received 25 g/day of extra virgin olive oil (EVO). Throughout the study, weight, blood pressure, and daily food intake were measured. Serum total cholesterol and low- and high-density lipoprotein cholesterol, triglycerides, and apolipoproteins A-I and B were measured at the end of each diet period. Results: Analysis of food intake showed that the daily diet is isocaloric for the butter regimen (2,537 ± 244 kcal/day) as well as for the VAO and EVO regimens (2,561± 246 and 2,560 ± 253 kcal/day, respectively). Analysis of the lipid intake showed a reduction in saturated fatty acids with VAO and EVO regimens (27 ± 1.4 and 26.4 ± 3.4%, respectively) as compared with the stabilization period (41.6 ± 2.4%). The analysis of serum lipids showed a significant increase in high-density lipoprotein cholesterol and apolipoprotein A-I in both VAO group (8.4%, p = 0.012, and 5.2%, p = 0.027, respectively) and EVO group (17.3%, p = 0.001, and 5.9%, p = 0.036, respectively). However, low-density lipoprotein cholesterol and apolipoprotein B (13.8%, p = 0.037, and 7.8%, p = 0.039, respectively) decreased significantly only in EVO group as compared with the stabilization period, while triglycerides decreased significantly by 17.5% (p = 0.039) only in VAO group. Conclusion: These results confirm the cholesterol-lowering effect of EVO and show for the first time the triglyceride-lowering effect of VAO in men.
Laboratoire de Recherche sur les Lipoprotéines
Faculté des Sciences Ben M’sik, BP 7955, Sidi Othman
Tel. +212 22 70 46 71, Fax +212 22 70 46 75, E-Mail firstname.lastname@example.org
Received: February 2, 2004
Accepted: October 11, 2004
Published online: July 13, 2005
Number of Print Pages : 6
Number of Figures : 0, Number of Tables : 4, Number of References : 34
Annals of Nutrition and Metabolism (European Journal of Nutrition, Metabolic Diseases and Dietetics)
Vol. 49, No. 3, Year 2005 (Cover Date: May-June 2005)
Journal Editor: Elmadfa, I. (Vienna)
ISSN: 0250–6807 (print), 1421–9697 (Online)
For additional information: http://www.karger.com/anm